
The European Medicines Agency (EMA) has begun its assessment of data from US-based Moderna, which has applied for the approval of its Spikevax in use as a Covid-19 booster vaccine, the EMA reports in a press release.
The hope is to use Spikevax for the re-vaccination of people aged 12 and over six months after they have received the second vaccine shot, with the aim of boosting the vaccine's effectiveness by prolonging a high Covid-19 protection.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app